Since its founding, Oneness Biotech has upheld its core values of science, integrity, and transparency, dedicating itself to the development of innovative drugs and medical devices, as well as global market expansion. Over the past sixteen years, we have built a solid foundation in two key areas: product development and corporate governance. Today, we are entering a new phase, accelerating our third core objective—business development—with a long-term global vision to enhance sustainable competitiveness.
In 2024, we made significant progress in expanding our footprint in the global wound care and diabetic foot ulcer markets. Our innovative diabetic foot ulcer treatment, FESPIXON® Cream, reached a major milestone in July with the signing of a commercialization agreement with China Resources Double-Crane Pharmaceutical Co., Ltd., marking the official launch of our entry into the China market. Meanwhile, our medical device Bonvadis® Cream received marketing approvals in Thailand, Saudi Arabia, and Australia. In June 2025, Bonvadis® Cream achieved a key breakthrough by securing an expanded indication in the United States for the treatment of full-thickness chronic wounds, significantly enhancing its international visibility and clinical value.
We understand that the successful adoption of wound care pharmaceuticals in clinical practice requires continuous engagement with healthcare professionals, making the launch of a new drug a highly challenging endeavor. Nevertheless, through the unwavering dedication of our team, we have actively expanded into key markets including the United States, China, the Middle East, and Latin America. We anticipate this will generate strong new growth momentum.
We pursue excellence not only in business development but also in corporate governance and sustainability. Oneness Biotech has been included in the S&P Global Sustainability Yearbook for three consecutive years. In 2023, we became the first pharmaceutical company in Taiwan to be selected and were honored with the Industry Mover Award. In 2024, we further advanced by becoming the first Taiwanese pharmaceutical company included in the DJSI Emerging Markets Index. Our progress continued in 2025, ranking in the top 10% of the global pharmaceutical industry in the Corporate Sustainability Assessment (CSA). In May 2025, the Taiwan Stock Exchange announced the results of the 11th Corporate Governance Evaluation, with Oneness Biotech earning the highest distinction—ranking among the top 5% in the TPEx-listed category and the top 10% of listed companies with a market capital of 10 billion TWD or more in the non-finance and non-electronics industry—for the fourth consecutive year. These domestic and international achievements highlight Oneness Biotech’s strong leadership and maturity in innovation management, information transparency, risk management, business ethics, and regulatory compliance.
We are also actively responding to the challenges of climate change by advancing carbon reduction and renewable energy initiatives. In 2024, we launched the construction of a 587.86 kW rooftop solar power system at our Nanchou plant. Completed and commissioned in the first half of 2025, the system is expected to generate approximately 660,000 kWh of electricity annually providing more than 25% of the plant’s total energy consumption. This marks a meaningful step forward in our journey toward low-carbon transformation.
Looking ahead, Oneness Biotech will remain committed to its mission of addressing unmet medical needs by strengthening our innovation capabilities, expanding our global business presence, and embedding sustainability into our core decision-making processes. We are confident that the synergy of research, governance, and sustainability will enable us to deliver long-term value and honor our shared commitments to shareholders, patients, society, and the environment.
